Question · Q4 2025
Nick Anderson asked for an update on the UK supply agreement, including early client feedback and future product iterations. He also questioned how the tariff landscape is influencing the onboarding of larger clients and the expansion roadmap for Ispire's Malaysian facility. Finally, he sought clarity on whether Q4 cannabis revenue represents a new run rate and the potential impact of rescheduling on Ispire's U.S. cannabis strategy.
Answer
CEO Michael Wang reported that while version one of the UK ODM product faced challenges due to the disposable ban, version two, launched in summer, is 'truly taking off,' contributing significantly to the $18 million backlog, with further iterations planned. He confirmed that tariffs are driving many companies to shift production outside China, accelerating interest in Ispire's Malaysian facilities. Mr. Wang noted that Ispire is expanding its second Malaysian facility to house up to 80 production lines and is considering a much larger third facility. Regarding cannabis, he stated that fiscal Q4 2025 was the 'bottom' for cannabis revenue, with new high-quality customers and products expected to drive growth, and that Ispire would re-evaluate investment if rescheduling occurs.
Ask follow-up questions
Fintool can predict
ISPR's earnings beat/miss a week before the call